MedTrace Logo

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

NCT03335943 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2017-11-08

No results posted yet for this study

Summary

This Study aims to evaluate the efficacy and safety of CDA-2 in the treatment of International Prognostic Scoring System (IPSS) Lower/Intermediate-risk myelodysplastic syndrome (MDS) in Chinese patients.

Conditions

  • Myelodysplastic Syndrome (MDS)

Interventions

DRUG

CDA-2 (Cell Differentiation Agent 2)

CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.

Sponsors & Collaborators

  • Harbin Institute of Hematology & Oncology

    collaborator UNKNOWN

  • Chinese Society of Hematology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-12-01
Completion
2020-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335943 on ClinicalTrials.gov